Melanotan II: Uses, Benefits & Research

What is Melanotan II?

Melanotan II (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, MW 920.1 Da) is a synthetic cyclic heptapeptide melanocortin receptor agonist originally developed for sunless tanning in the 1980s. It acts on MC1R (melanin production), MC3R (sexual motivation and appetite), and MC4R (sexual function and erection), producing dual effects on pigmentation and sexual function.

Melanotan II’s safety story is dominated by one critical concern: documented melanoma case reports in the medical literature. The mechanism that produces tanning (MC1R stimulation of melanocytes) is biologically linked to melanoma risk, making this a plausible rather than coincidental adverse effect. Melanotan II is not FDA approved, is WADA-prohibited, and is likely to remain Category 2 restricted specifically because of cancer risk concerns.

It is critical to distinguish Melanotan II from PT-141 (bremelanotide), which is in the same peptide family but has a different structure, different safety profile, and is FDA-approved for hypoactive sexual desire disorder.

Mechanism of Action

Melanotan II stimulates melanocortin receptors with broad activity across MC1R, MC3R, and MC4R. MC1R activation drives melanogenesis — increasing tyrosinase activity and melanin production in melanocytes, producing skin darkening. MC3R and MC4R activation produces the sexual arousal and erectogenic effects, as well as appetite suppression.

The mechanistic link to melanoma is direct and biologically plausible: MC1R activation stimulates melanocyte proliferation, the same cell type that gives rise to melanoma. Case reports document melanoma arising at or near injection sites, and no safe threshold dose has been established. Fair-skinned individuals with MC1R variants, who already have elevated baseline melanoma risk, may be at particular risk.

Melanotan II has a half-life of approximately 30-60 minutes after subcutaneous injection with good bioavailability.

Clinical Evidence

Human Studies

Melanotan II has approximately 20 human studies and 3-5 RCTs, primarily from the 1980s-2000s.

Tanning Studies (1989-1991): Early RCTs (N=15-20) demonstrated significant, dose-dependent melanin increase with subcutaneous dosing.

Erectile Dysfunction Studies (2000-2006): Small RCTs (N=10-20) by Wessells et al. showed improved erections and sexual arousal.

Melanoma Case Reports: Multiple documented cases of melanoma at or near injection sites, including melanoma in situ (2012), oral mucosal melanoma linked to nasal spray use (2025), and systemic toxicity with rhabdomyolysis (PMID: 23121206). The key reference is “Melanoma associated with the use of melanotan-II” (PMID: 24355990).

These case reports represent the highest-level safety signal for a compound with limited RCT safety data. Development appears to have stalled due to these safety concerns and the lack of an FDA pathway.

Preclinical Evidence

The melanocortin receptor system is well-characterized. MC1R’s role in melanocyte biology and melanoma susceptibility is extensively documented in the scientific literature, providing the biological plausibility for the observed adverse events.

Drug Interactions & Contraindications

PDE5 inhibitors (sildenafil, tadalafil) have a documented interaction with additive vasodilation and erectile effects, increasing hypotension risk. Theoretical interactions exist with antihypertensives, alpha-blockers, immunosuppressants, and melanoma treatments.

Melanotan II is strongly contraindicated in patients with any history of melanoma or dysplastic nevi, cardiovascular disease, and during pregnancy/breastfeeding. Regular dermatological screening is strongly recommended for anyone who has used this compound.

Safety & Side Effects

The safety profile of Melanotan II is defined by the melanoma risk. Documented adverse effects include melanoma case reports at injection sites, nausea (common, dose-related), facial flushing, spontaneous erections with priapism risk, generalized skin darkening, yawning, appetite suppression, and a case of systemic toxicity with rhabdomyolysis.

The melanoma concern is not theoretical — it is documented in case reports with a biologically plausible mechanism (MC1R directly stimulates melanocytes). No safe dose threshold has been established, and no long-term safety studies have been conducted.

Honest Bottom Line

Melanotan II has documented melanoma case reports in the medical literature — not theoretical concerns, but actual patients who developed cancer while using this compound. The mechanism is biologically plausible: MC1R stimulation of melanocytes is the same pathway involved in melanoma development.

As of March 2026, Melanotan II is not FDA approved, is WADA-prohibited, and is likely to remain Category 2 restricted specifically because of the melanoma signal. The tanning indication is cosmetic and not therapeutic. For the sexual dysfunction indication, FDA-approved PT-141 (bremelanotide) provides an alternative from the same peptide family without the accumulated melanoma case reports. Patients should not use Melanotan II — the risk is documented, the benefit is cosmetic or unapproved, and approved alternatives exist.